Mirena IUD hair loss is a concern raised by a growing number of users of the levonorgestrel-releasing intrauterine system (LNG-IUS) in the UK. The Mirena coil is widely prescribed for contraception and heavy menstrual bleeding, but some individuals notice increased hair shedding or thinning after insertion. Whilst alopecia is listed as an uncommon side effect in the Mirena summary of product characteristics, the precise prevalence and mechanism remain incompletely understood. This article explores the potential hormonal link, how common this side effect may be, when to seek medical advice, and what management options are available.

Can the Mirena Coil Cause Hair Loss?

Hair loss is listed as an uncommon side effect of the Mirena coil in its SmPC, potentially affecting 1 in 100 to 1 in 1,000 users, though other causes must be excluded before attributing alopecia to the device.

Experiencing these side effects? Our pharmacists can help you navigate them →

The Mirena coil is a levonorgestrel-releasing intrauterine system (LNG-IUS) widely used in the UK for contraception and the management of heavy menstrual bleeding. It releases a small, continuous dose of the synthetic progestogen levonorgestrel directly into the uterine cavity. While it is generally well tolerated, some users report experiencing hair thinning or shedding after insertion.

Hair loss — medically referred to as alopecia — is listed as an uncommon side effect in the Mirena patient information leaflet and summary of product characteristics (SmPC), meaning it may affect between 1 in 100 and 1 in 1,000 users. Patterns reported include diffuse thinning and telogen effluvium (a temporary, stress-related shedding); the precise pattern most commonly associated with the Mirena is not clearly established in the published evidence, which is largely based on spontaneous adverse event reports and observational data rather than large randomised controlled trials.

It is important to note that hair loss is a multifactorial condition. Thyroid dysfunction, iron deficiency anaemia, nutritional deficiencies, and significant psychological stress are all common causes that must be excluded before attributing hair loss solely to the Mirena coil. There is no definitive causal proof that the Mirena coil directly causes hair loss in all affected individuals, and many users experience no change in hair density whatsoever. A thorough clinical assessment is always recommended before drawing conclusions.

If you think you may be experiencing a side effect from the Mirena coil, you can report it to the MHRA via the Yellow Card Scheme at yellowcard.mhra.gov.uk.

How Levonorgestrel May Affect Hair Growth

Levonorgestrel has mild androgenic activity and may theoretically miniaturise hair follicles in genetically predisposed individuals, even at the low systemic levels absorbed from the Mirena coil.

To understand the potential link between the Mirena coil and hair loss, it helps to consider the pharmacology of levonorgestrel. This synthetic progestogen has mild androgenic (testosterone-like) activity, meaning it can weakly bind to androgen receptors in the body. Androgens play a well-established role in hair follicle biology — elevated androgen activity can shorten the anagen (growth) phase of the hair cycle and miniaturise follicles, particularly in individuals who are genetically predisposed to androgenetic alopecia.

Not sure if this is normal? Chat with one of our pharmacists →

Although the Mirena coil delivers levonorgestrel locally within the uterus, a small amount is absorbed into the systemic circulation. Serum levonorgestrel levels from the Mirena are considerably lower than those achieved with oral contraceptive pills containing the same hormone. According to the Mirena SmPC and FSRH guidance on intrauterine contraception, most users continue to ovulate normally, and consistent suppression of ovarian oestrogen production does not typically occur. Nevertheless, in susceptible individuals — particularly those with a personal or family history of hormone-sensitive hair loss — even low systemic levels of an androgenic progestogen may theoretically contribute to follicular miniaturisation.

The possibility that mild androgenic activity from systemic levonorgestrel could influence hair growth in genetically predisposed individuals is biologically plausible, but the evidence supporting a direct causal link is limited. Individual responses vary considerably based on genetic sensitivity and baseline hormone levels, and this hormonal interplay is not fully understood.

How Common Is Hair Loss With the Mirena Coil?

The Mirena SmPC classifies alopecia as uncommon, occurring in fewer than 1 in 100 users, though anecdotal reports suggest subjective hair thinning may be under-captured in clinical trial data.

Formally, the Mirena SmPC, as approved by the Medicines and Healthcare products Regulatory Agency (MHRA), classifies alopecia as an uncommon adverse effect, occurring in fewer than 1 in 100 users. However, anecdotal reports and online patient communities suggest that the subjective experience of hair thinning may be more widespread than clinical trial data capture, possibly because:

• Hair loss can be gradual and difficult to attribute to a specific cause

• Participants in clinical trials may not always report cosmetic changes proactively

• Individual genetic susceptibility varies significantly

• Spontaneous adverse event reporting is subject to both under-reporting and reporting bias

It is worth noting that the evidence base for this side effect is largely derived from spontaneous adverse event reporting and observational data rather than large randomised controlled trials specifically designed to measure hair outcomes. This makes precise prevalence estimates challenging.

For context, hair loss affects a significant proportion of the general population regardless of contraceptive use. According to the British Association of Dermatologists (BAD), female pattern hair loss becomes increasingly common with age, and many women experience some degree of hair thinning over their lifetime. Distinguishing Mirena-related hair loss from these background rates requires careful clinical evaluation, including a detailed timeline correlating the onset of hair shedding with the date of coil insertion.

When to Speak to Your GP or Gynaecologist

Seek a GP or gynaecologist appointment if hair loss is rapid, patchy, or accompanied by symptoms such as fatigue or cold intolerance, which may indicate an underlying thyroid or systemic condition.

If you have noticed increased hair shedding, thinning at the crown, or a widening parting since having the Mirena coil fitted, it is reasonable to discuss this with your GP or gynaecologist. You should seek an appointment promptly if:

• Hair loss is rapid or severe, affecting large areas of the scalp

• Patchy hair loss is present, which may suggest alopecia areata — an autoimmune condition unrelated to hormonal contraception

• Hair loss is accompanied by other symptoms such as fatigue, weight changes, cold intolerance, or irregular periods, which may indicate an underlying thyroid disorder

• You notice scalp symptoms such as pain, redness, or scaling, which may suggest a scarring alopecia requiring prompt dermatology review

• You have noticed hair loss elsewhere on the body, including eyebrows or eyelashes

• The hair loss is causing significant psychological distress

Your GP will typically arrange baseline blood tests to exclude common treatable causes. Reasonable first-line investigations include a full blood count (to check for anaemia), serum ferritin (iron stores), and thyroid function tests. Androgen levels — such as total testosterone, sex hormone-binding globulin (SHBG), and free androgen index — are not routinely indicated unless there are clinical features suggesting hyperandrogenism, such as acne, hirsutism, or irregular menstrual cycles. In such cases, prolactin may also be checked.

A referral to a dermatologist or specialist hair clinic may be appropriate if initial investigations are unremarkable and hair loss persists. Trichology is not a statutorily regulated profession in the UK, and trichologists are not generally available through the NHS; a dermatologist is the preferred specialist referral route.

It is important not to have the Mirena removed without first discussing the decision with a healthcare professional, as this may leave you without effective contraception or without treatment for heavy menstrual bleeding, both of which carry their own health implications.

Managing Hair Loss While Using the Mirena Coil

Management includes excluding nutritional deficiencies, avoiding damaging hair practices, and considering topical minoxidil — the only MHRA-licensed topical treatment for female pattern hair loss in the UK.

If investigations confirm that no underlying medical cause is responsible for your hair loss, and a temporal relationship with Mirena insertion is suspected, there are several management strategies worth discussing with your doctor.

General supportive measures include:

• Ensuring a balanced, varied diet with adequate iron, zinc, and protein, as nutritional deficiencies can compound hormonally driven hair loss. Routine biotin supplementation is not recommended unless a deficiency has been confirmed, as biotin can interfere with certain laboratory tests and there is limited evidence for its use in the absence of deficiency

• Avoiding harsh chemical treatments, excessive heat styling, and tight hairstyles that place mechanical stress on follicles

• Using gentle shampoos and avoiding vigorous towel-drying; these measures carry low risk, though the evidence base is limited

Topical minoxidil is the only MHRA-licensed topical treatment for female pattern hair loss available in the UK. The licensed options for women are:

• 2% minoxidil solution, applied twice daily

• 5% minoxidil foam, applied once daily

Note that the 5% minoxidil solution is not licensed for use in women. Minoxidil works by prolonging the anagen phase and increasing follicular size. It requires consistent, long-term use to maintain benefit, and results typically become apparent after three to six months of regular application. An initial increase in shedding during the first few weeks is common and usually temporary. Scalp irritation may also occur. Minoxidil should not be used during pregnancy or whilst breastfeeding; if you are planning a pregnancy, discuss this with your GP or pharmacist before starting treatment.

For some individuals, hair loss may stabilise over time, though this is variable and not guaranteed. Keeping a photographic record of hair density can be a useful way to objectively monitor progression or improvement and to inform discussions with your clinician. Psychological support, including referral to a counsellor or support group, may also be beneficial given the well-documented impact of hair loss on self-esteem and mental wellbeing.

Alternative Contraceptive Options to Discuss With Your Doctor

Alternatives include combined hormonal contraceptives with lower-androgenic progestogens or the copper IUD, though each carries its own risk profile and should be chosen following UKMEC assessment with a clinician.

If hair loss is significantly affecting your quality of life and is thought to be related to the Mirena coil, it is entirely reasonable to explore alternative contraceptive methods with your GP or a sexual health clinician. Removal of the Mirena should always be accompanied by a clear plan for ongoing contraception or management of any gynaecological conditions for which it was originally prescribed.

Combined hormonal contraceptives (CHCs) contain both an oestrogen and a progestogen. Some CHCs contain progestogens with lower androgenic activity, such as drospirenone, which may theoretically be preferable for individuals prone to androgen-sensitive hair loss; however, evidence that CHCs reliably improve hair loss is limited, and any choice should follow FSRH guidance and UK Medical Eligibility Criteria (UKMEC) assessment. CHCs carry their own risk profile, including a small increased risk of venous thromboembolism, and are not suitable for everyone.

Cyproterone acetate-containing preparations should not be used routinely for contraception or hair loss. The MHRA has issued a Drug Safety Update warning of an increased risk of meningioma (a type of brain tumour) associated with cyproterone acetate, particularly at higher cumulative doses. These preparations have restricted licensed indications and should only be used under specialist supervision when other options are unsuitable.

If anti-androgen treatment for hair loss is being considered, this is best discussed with a dermatologist, who may consider options such as spironolactone on an off-label basis where appropriate.

Non-hormonal options include:

• The copper IUD (non-hormonal coil), which provides highly effective long-term contraception without any hormonal influence on hair follicles. However, it is important to note that the copper IUD may increase menstrual bleeding and cramping, which is a relevant consideration for those who were using the Mirena to manage heavy menstrual bleeding

• Barrier methods such as condoms, though these are less effective as sole contraception

• Fertility awareness methods, which require training and consistent use to be reliable

For those using the Mirena primarily to manage heavy menstrual bleeding rather than for contraception, NICE guidance (NG88) supports the use of tranexamic acid, mefenamic acid, or combined hormonal contraceptives as alternatives, among other options. A shared decision-making conversation with your clinician, weighing the benefits and risks of each option in the context of your individual health history, is the most appropriate next step.

Frequently Asked Questions